It is an extremely warm, lightweight jacket that works well over both a base layer and a fleece, with dedicated articulation ...

Monthly cloud outages, like the recent Azure one, continue to disrupt enterprises worldwide. The culprits include hiring challenges, neglected resilience, and increasing complexity.

Intervertebral disc degeneration (IVDD) constitutes a major source of chronic low back pain and functional limitation worldwide, substantially impairing physical activity, sports performance, and ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Microsoft introduces unique hostnames for Azure Functions and Logic Apps, reducing endpoint security risks. Non-enumerable Azure app URLs limit reconnaissance, scanning, targeted attacks and dangling ...

Microsoft spent $88.7B on capex in fiscal 2025 for AI infrastructure. This exceeded the projected $80B. Analysts set a $631 price target for Microsoft stock. This implies 30% upside from current ...

Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β-cells in the pancreas. Regulatory T cells (Tregs) are essential for maintaining immune tolerance, but they ...

Cloud security architect and advisor Steven Smiley walked attendees through a slate of notable AWS announcements in a Virtualization & Cloud Review webcast today. The presentation held by Smiley, an ...

As infrastructure ages, one question shapes the future of cities: How do we know the materials we build with will last? At the University of Miami College of Engineering, Prannoy Suraneni, associate ...

Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo ...

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV) ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced ...